Navigation Links
Spherix Incorporated to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
Date:9/6/2011

BETHESDA, Md., Sept. 6, 2011 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that Dr. Claire Kruger, Chief Executive Officer, and Dr. Robert Lodder, President, will be presenting a corporate overview at the Rodman & Renshaw 13th Annual Healthcare Conference at 3:40 p.m. on September 12, 2011, in Metropolitan West of the Waldorf Astoria in New York.  The conference will be held from September 11-13, 2011.

A live audio and archived webcast of Spherix's presentation will be available through the Investor Relations section of the Company's website.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis.  Biospherics is actively seeking a pharmaceutical partner to continue the development of its Phase 3 compound for the treatment of diabetes, D-tagatose, while exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke.  Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Spherix Announces Second Quarter Financial Results
2. Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions in Serum Triglycerides in Preclinical Testing
3. Spherix Announces Registered Direct Offering of $2.77 Million
4. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
5. Spherix Announces Third Quarter 2010 Financial Results
6. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
7. Spherix Announces Institutional Investors Purchase $5.25 Million of Convertible Preferred Stock and Warrants
8. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
9. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
10. Spherix Reports Third Quarter 2009 Earnings
11. Spherix Announces Positive Phase 2 Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. ... saving and improving the lives of pets, today announced ... of the New Animal Drug Application (NADA) for Zimeta™ ... field study (KB0120) of Zimeta for the control of ... Company. --> --> ...
(Date:2/11/2016)... 2016  Governor Andrew M. Cuomo today announced a ... throughout Western New York . This ... Polytechnic Institute, includes a major expansion of Athenex,s North ... Buffalo , as well as the creation of ... Dunkirk . The combined projects are expected ...
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016 Potrero Medical, ... is pleased to announce the appointment of George M. ... San Antonio, TX , WellMed is one ... over 200,000 patients and HMO members in Texas ... WellMed in 1990 out of his own internal medicine practice, ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner Tal ... and no time to decompress, Rabinowitz found herself drawn to a casual meditation class ... impact on her life, implementing a 20-minute-per-day meditation practice with her team. After her ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a discovery, ... real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... The Jones ... other communities across eastern Texas, is launching a cooperative charity drive with the Tarrant ... , Serving more than 50,000 individuals and families in need, the Tarrant County Food ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ ... Nevada, announced a partnership with San Ramon Regional Medical Center. Under the collaboration, the ... as a way to accommodate a more certain time frame for donor families for ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today announces the launch ... component of “Revolutionizing Cancer Care” is distributed within the February 12 issue of ... a circulation of approximately 250,000 copies and an estimated readership of 750,000 readers. ...
Breaking Medicine News(10 mins):